Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
DOI:
https://doi.org/10.2340/00015555-3245Keywords:
ixekizumab, psoriasis, disease managementAbstract
Treatment goals defined by the absolute Psoriasis Area and Severity Index (PASI) scores offer certain advantages in the clinical setting. In order to investigate potential treatment targets, this study evaluated absolute PASI outcomes relative to other measures of response using data from two randomized clinical trials of patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept, or placebo (n=2,567). Response was assessed throughout 12 weeks as the proportion of patients achieving absolute PASI band cut-offs who also reached established response criteria. Most PASI band ?2 responders also achieved PASI 90 (70.1?100%), static Physician?s Global Assessment (0,1) (91.3?96.1%), Dermatology Life Quality Index (0,1) (63.0?67.7%), Patient Global Assessment of Disease Severity (0,1) (80.3?86.7%), and Itch Numeric Rating Scale improvement ?4 (87.2?87.6%). Agreement sharply decreased for less stringent PASI criteria. These data indicate that PASI ?2 represents significantly meaningful clinical and health-related quality of life improvements and may be a suitable treatment target for moderate-to-severe plaque psoriasis.Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Luís Puig, Martin Dossenbach, Lovisa Berggren, Anders Ljungberg, Claus Zachariae
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.